Bolt Biotherapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing Boltbody immuno-oncology antibody-drug conjugates, which combine tumor-targeting antibodies with immune-stimulating molecules to attack cancer cells while activating the immune system against tumors.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Coastlands Capital LP10% Owner | Buy | $319K | 50,000at $6.38 | Nov 9, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BOLT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.